Post marketing safety surveillance Requirements for Natural Health Products in Japan: A Guide for Canadian Manufacturers

Introduction

The Japanese market for natural health products (NHPs) represents a significant opportunity for Canadian manufacturers, but it is also one of the most regulated globally. Japan’s pharmacovigilance framework is rigorous, reflecting the country’s high standards for drug safety, quality, and efficacy. For Canadian NHP manufacturers seeking to export to Japan, understanding the regulatory framework, key agencies involved, and specific pharmacovigilance requirements is essential to ensure compliance and successful market entry.

This comprehensive review synthesizes the latest regulatory intelligence, including the role of the PMDA and MHLW, specific pharmacovigilance obligations, and practical considerations for Canadian manufacturers. It also highlights recent reforms and case insights, benchmarked against global standards and tailored for Canadian exporters.

Regulatory Framework and Key Agencies in Japan

Japan’s pharmacovigilance system for NHPs is primarily governed by the Pharmaceuticals and Medical Devices Act (PMD Act), enacted in 2014, which replaced the older Pharmaceutical Affairs Law. This act establishes the legal framework ensuring the quality, efficacy, and safety of pharmaceuticals and medical devices, including NHPs. The PMD Act classifies products into categories such as prescription drugs, over-the-counter drugs, medical devices, and regenerative medicine products, each with distinct regulatory pathways.

The Pharmaceuticals and Medical Devices Agency (PMDA) is the scientific and technical regulatory body responsible for reviewing the quality, safety, and efficacy of medical products. The PMDA operates under the Ministry of Health, Labour and Welfare (MHLW), which handles policy-making, pricing, and final marketing authorizations. This separation of responsibilities ensures a clear, efficient, and thorough regulatory process.

The PMDA’s role includes pre-submission consultations, post-marketing safety surveillance, and guidance on regulatory science. The MHLW focuses on policy implementation and regulatory enforcement, including recalls and warnings. Both agencies are involved in international harmonization efforts and periodic reviews of regulatory strategies to ensure ongoing compliance and regulatory efficiency

Classification of NHPs in Japan and Implications for Pharmacovigilance

In Japan, NHPs may fall under different regulatory categories depending on their intended use, composition, and claims. These categories include:

• Foods for Specified Health Uses (FOSHU): Require formal application to the MHLW and must demonstrate specific health benefits.

• Foods with Function Claims (FFC): Require notification to the Consumer Affairs Agency (CAA) and must comply with labeling and safety standards.

• Regular Health Supplements: Must comply with general food regulations unless they make health claims.

The classification determines the regulatory pathway and pharmacovigilance expectations. For instance, products classified as drugs or quasi-drugs face stricter pharmacovigilance requirements, including adverse event reporting, risk management plans, and post-marketing surveillance

Specific Pharmacovigilance Requirements

Adverse Event Reporting

Japan’s pharmacovigilance system requires manufacturers to monitor and report adverse drug reactions (ADRs) immediately. The PMDA mandates that adverse effects must be reported within 15 or 30 days, depending on the nature of the event, in accordance with ICH E2B(R3) guidelines. This reporting is mandatory for marketing authorization holders and must be submitted to the MHLW.

A unique Japanese requirement is the all-case surveillance (PMACS), which mandates manufacturers to track safety in every patient using a new drug. This level of surveillance is uncommon globally and underscores Japan’s emphasis on comprehensive safety monitoring

Risk Management Plans (RMPs)

The PMDA requires companies to establish comprehensive Post-Marketing Surveillance (PMS) plans and Risk Management Plans (RMPs). These plans must assess potential risks, prepare reports recommending risk management methods, and implement supplementary measures such as Post-Authorization Safety Studies (PASS). The goal is to identify and address potential adverse events promptly, thereby strengthening the pharmacovigilance system.

Differences in Pharmacovigilance Expectations Between NHPs and Conventional Drugs

While NHPs and conventional drugs share many pharmacovigilance requirements, NHPs often face additional scrutiny due to their diverse compositions and potential interactions with other products. The PMDA expects manufacturers to maintain robust safety reporting systems and conduct re-examinations of drug safety after approval. The Good Vigilance Practice (GVP) Ordinance defines obligations for quality systems and pharmacovigilance, including early post-marketing phase vigilance during the first six months after launch

Practical Considerations for Canadian Manufacturers

Need for a Local Pharmacovigilance Contact or Representative

Canadian manufacturers must appoint a Marketing Authorization Holder (MAH) in Japan or establish a local subsidiary to hold the MAH license. This is a legal requirement for all regulatory obligations, including pharmacovigilance activities. The MAH is responsible for filing initial applications, responding to PMDA queries, managing post-approval changes, conducting post-marketing pharmacovigilance under the GVP ordinance, and executing safety-related label changes

• Implement Robust Pharmacovigilance Systems: Develop comprehensive safety reporting, risk management, and post-marketing surveillance plans tailored to Japan’s requirements.

• Ensure Accurate Translation and Labeling: All documentation and labeling must be accurately translated into Japanese and comply with MHLW standards.

• Stay Updated on Regulatory Reforms: Keep abreast of the latest PMDA and MHLW updates, such as the 2025 PMD Act amendments, to ensure ongoing compliance.

• Engage in Early Consultation with PMDA: Leverage pre-submission consultations to clarify expectations and avoid costly mistakes.

Conclusion

The Japanese pharmacovigilance framework for natural health products is comprehensive and stringent, reflecting the country’s high standards for drug safety and efficacy. Canadian manufacturers seeking to export NHPs to Japan must navigate a complex regulatory landscape overseen by the PMDA and MHLW. Key requirements include rigorous adverse event reporting, stringent labeling and packaging standards, and comprehensive risk management plans.

Recent reforms, such as the 2025 PMD Act amendments, introduce revocation mechanisms and emphasize balancing expedited approvals with evidence-based safety. Canadian manufacturers must invest in local regulatory infrastructure, implement robust pharmacovigilance systems, and ensure compliance with language and documentation requirements.

By understanding and addressing these regulatory demands, Canadian NHP manufacturers can successfully enter the Japanese market while ensuring the safety and efficacy of their products in compliance with Japan’s rigorous pharmacovigilance framework.

References

• Ministry of Health, Labour and Welfare (JP). Pharmaceuticals and Medical Devices Act (PMD Act) [Internet]. Tokyo: Ministry of Health, Labour and Welfare; [cited 2026 Jun 19]. Available from: https://www.mhlw.go.jp

• Pharmaceuticals and Medical Devices Agency. Pharmaceuticals and Medical Devices Agency (PMDA) [Internet]. Tokyo: PMDA; [cited 2026 Jun 19]. Available from: https://www.pmda.go.jp

• Ministry of Health, Labour and Welfare (JP). Food Sanitation Act [Internet]. Tokyo: Ministry of Health, Labour and Welfare; [cited 2026 Jun 19]. Available from: https://www.mhlw.go.jp

• Pharmaceuticals and Medical Devices Agency. Good Vigilance Practice (GVP) Ordinance [Internet]. Tokyo: PMDA; [cited 2026 Jun 19]. Available from: https://www.pmda.go.jp

• Consumer Affairs Agency (JP). Standards for Foods with Function Claims (FFC) [Internet]. Tokyo: Consumer Affairs Agency; [cited 2026 Jun 19]. Available from: https://www.caa.go.jp